Log In
BCIQ
Print this Print this
 

Biosimilar trastuzumab (DA-3111)

  Manage Alerts
Collapse Summary General Information
Company Dong-A Socio Holdings Co. Ltd.
DescriptionBiosimilar trastuzumab, a humanized mAb against epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionBinds HER2/neu; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation
PartnerDong-A ST Co. Ltd.;
Meiji Seika Pharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/03/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today